In cholinergic synapses, there are two main types of receptors for acetylcholine: ionotropic and metabotropic. Ionotropic receptors, also known as nicotinic acetylcholine receptors, are ligand-gated ion channels. When acetylcholine binds to these receptors, they open directly, allowing ions to flow across the membrane, leading to a rapid response. Metabotropic receptors, also known as muscarinic acetylcholine receptors, are G-protein coupled receptors. They do not open ion channels directly. Instead, they activate a secondary messenger system inside the cell, which eventually leads to ion channel opening or other cellular responses. This process is generally slower but can lead to more prolonged and varied effects.

The concentration of calcium ions in the pre-synaptic neuron has a critical role in regulating neurotransmitter release at cholinergic synapses. A rise in calcium ion concentration, triggered by the arrival of an action potential, induces the fusion of synaptic vesicles with the pre-synaptic membrane, leading to the release of acetylcholine. The amount of calcium influx directly influences the amount of neurotransmitter released; a higher concentration of calcium ions results in a greater release of acetylcholine. This regulation is crucial for controlling the strength and timing of synaptic transmission, affecting everything from muscle contraction to cognitive functions.

Cholinergic synapses play a significant role in the pathophysiology of several neurological disorders. For example, in Alzheimer's disease, there is a marked decrease in cholinergic neurons in the brain, leading to cognitive decline. Enhancing cholinergic transmission through cholinesterase inhibitors is a common treatment approach. In Parkinson's disease, the balance between dopaminergic and cholinergic systems is disrupted, and anticholinergics can help reduce tremors and muscle rigidity. Myasthenia gravis, an autoimmune disorder, involves the destruction or blocking of acetylcholine receptors, leading to muscle weakness. Understanding the role of cholinergic synapses in these disorders is crucial for developing effective treatments.

Synaptic plasticity in cholinergic synapses involves changes in the strength and efficacy of synaptic transmission over time. This plasticity can occur through several mechanisms. One key mechanism is the alteration in the number of acetylcholine receptors on the post-synaptic membrane. Long-term potentiation (LTP) or long-term depression (LTD) can occur, depending on the pattern of activity at the synapse. For instance, a sustained increase in acetylcholine release can lead to LTP, enhancing synaptic transmission. Additionally, changes in the amount of neurotransmitter released and the sensitivity of the post-synaptic neuron to acetylcholine can also contribute to synaptic plasticity, allowing the synapse to adapt to different signaling demands.

Anticholinergics are drugs that inhibit the action of acetylcholine at cholinergic synapses. They work by blocking the acetylcholine receptors, particularly in the parasympathetic nervous system, leading to decreased activity. This results in effects such as dilated pupils, increased heart rate, and reduced secretions. On the other hand, cholinesterase inhibitors prevent the breakdown of acetylcholine by inhibiting the enzyme acetylcholinesterase. This leads to an increase in acetylcholine concentration at the synapse, thereby enhancing its action. These inhibitors are often used in the treatment of Alzheimer's disease to improve cognition, as they enhance cholinergic transmission in the brain.